| Tenosynovial giant cell tumor: incidence, prevalence, patient characteristics, and recurrence. A registry-based cohort study in Denmark V Ehrenstein, SL Andersen, I Qazi, N Sankar, AB Pedersen, R Sikorski, ... The Journal of rheumatology 44 (10), 1476-1483, 2017 | 88 | 2017 |
| Randomized phase III ANGEL study of rivoceranib (apatinib)+ best supportive care (BSC) vs placebo+ BSC in patients with advanced/metastatic gastric cancer who failed≥ 2 prior … YK Kang, WK Kang, M Di Bartolomeo, I Chau, HH Yoon, S Cascinu, ... Annals of Oncology 30, v877-v878, 2019 | 61 | 2019 |
| A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented … KK Sankhala, JY Blay, KN Ganjoo, A Italiano, AB Hassan, TM Kim, V Ravi, ... Journal of Clinical Oncology 35 (15_suppl), 11078-11078, 2017 | 38 | 2017 |
| Abstract B143: A phase 1a/1b study of FPA008 in combination with nivolumab in patients with selected advanced cancers J Brahmer, D Rasco, M Chen, E Masteller, I Qazi, S Rogers, N Sankar, ... Cancer Immunology Research 4 (1_Supplement), B143-B143, 2016 | 11 | 2016 |
| A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment. AB El-Khoueiry, N Tchekmedyian, RE Sanborn, JA Peguero, K Pulver, ... Journal of Clinical Oncology 38 (15_suppl), 3112-3112, 2020 | 9 | 2020 |
| Oncolytic Seneca Valley Virus (SVV-001) Overcomes Checkpoint Inhibitor Resistance and Demonstrates a Systemic Anti-Tumor Response in a Syngeneic Tumor Model PL Hallenbeck, S Chada, N Sankar, A Chauhan Endocrine Abstracts 89, 2023 | 3 | 2023 |
| Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor SH Kizilbash, A El-Khoueiry, RE Lerner, PC Ma, M Almubarak, K Mody, ... European Journal of Cancer 138, S11-S12, 2020 | 3 | 2020 |
| A phase II open-label, multicenter, study to evaluate the efficacy and safety of rivoceranib in subjects with recurrent or metastatic adenoid cystic carcinoma. H Kang, AL Ho, J Muzaffar, DW Bowles, SB Kim, MJ Ahn, GJ Hanna, ... Journal of Clinical Oncology 38 (15_suppl), TPS6597-TPS6597, 2020 | 2 | 2020 |
| Phase I study to evaluate the safety and efficacy of rivoceranib (apatinib) and nivolumab in patients with unresectable or metastatic cancer SP Chawla, VS Chua, EM Gordon, A Moradkhani, K Kim, D Quon, ... Journal of Clinical Oncology 37 (8_suppl), 18-18, 2019 | 2 | 2019 |
| A pilot clinical study of VAL-413 (oral irinotecan HCl) in patients with recurrent pediatric solid tumors. D Brown, JA Bacha, JI Geller, PA Thompson, JE Oesterheld, S Kanekal, ... Journal of Clinical Oncology 40 (16_suppl), TPS10063-TPS10063, 2022 | 1 | 2022 |
| Abstract P081: In vitro activity and efficacy of novel dual PARP-HDAC inhibitors S Truong, F Ghaidi, L Ramos, J Joshi, D Brown, N Sankar, J Langlands, ... Molecular Cancer Therapeutics 20 (12_Supplement), P081-P081, 2021 | 1 | 2021 |
| THER-01. Preclinical development of EO1001, a novel irreversible brain penetrating PAN-ErbB inhibitor W Shen, J Bacha, D Brown, S Kanekal, N Sankar, ZZ Wang, H Pedersen, ... Neuro-oncology Advances 1 (Suppl 1), i10, 2019 | 1 | 2019 |
| Anti-CSF1R antibodies for treating PVNS R Sikorski, J Hambleton, N Sankar US Patent 10,040,858, 2018 | 1 | 2018 |
| A phase I trial of intratumoral STX-001: A novel self-replicating mRNA expressing IL-12 alone or with pembrolizumab in advanced solid tumors. JJ Luke, LC Kennedy, N Sankar, AM Menzies, ACJ van Akkooi, ... Journal of Clinical Oncology 42 (16_suppl), TPS2696-TPS2696, 2024 | | 2024 |
| Abstract CT058: A multicenter phase 1-2a clinical study of Orotecan (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors J Geller, P Thompson, J Oesterheld, A Kim, M McManus, J Bacha, ... Cancer Research 84 (7_Supplement), CT058-CT058, 2024 | | 2024 |
| Abstract A037: Exploring the therapeutic effectiveness of EO3001 in the treatment of clear cell ovarian cancers with ARID1A mutations Y Ding, LY Li, JY Zhang, F Kabeer, TY Lam, F Kalantari, J Bacha, ... Cancer Research 84 (5_Supplement_2), A037-A037, 2024 | | 2024 |
| A pilot clinical study of oral irinotecan HCl (VAL-413) in patients with recurrent pediatric solid tumors. JA Bacha, D Brown, JI Geller, JE Oesterheld, M McManus, S Kanekal, ... Journal of Clinical Oncology 41 (16_suppl), TPS10073-TPS10073, 2023 | | 2023 |
| Abstract CT135: A pilot clinical study of orotecan (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors J Bacha, D Brown, S Kanekal, N Sankar, L Lopez, N Yam, L Wagner, ... Cancer Research 83 (8_Supplement), CT135-CT135, 2023 | | 2023 |
| Oncolytic Seneca Valley Virus (SVV-001) Overcomes Checkpoint Inhibitor Resistance and Demonstrates a Systemic Anti-tumor Response in a Syngeneic Tumor Model N Sankar Endocrine Abstracts, https://doi.org/10.1530/endoabs.89.B5, 2022 | | 2022 |
| A novel dual PARP-HDAC inhibitor for treatment of Ewing sarcoma S Truong, B Zhai, F Ghaidi, L Ramos, J Joshi, D Brown, N Sankar, ... European Journal of Cancer 174, S39, 2022 | | 2022 |
